Full-Time

Quality Compliance Lead

Confirmed live in the last 24 hours

Legend Biotech

Legend Biotech

1,001-5,000 employees

Develops and commercializes cell therapies

No salary listed

Senior

Bridgewater Township, NJ, USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Requirements
  • A minimum of a Bachelor’s Degree in Engineering, Science or equivalent technical discipline is required
  • A minimum of five (5) years of experience in Quality Assurance/ Quality Systems or Compliance
  • Experience conducting internal audits (self-inspection), including writing audit reports, writing observations, and follow-through of observation resolution
  • Experience in front room/ back room roles for external audits
  • Experience working with quality systems is required
Responsibilities
  • Successfully support the implementation, execution, and improvement of the internal audit process.
  • Support the planning and execution of internal audits for all quality system areas for the manufacturing site; write audit reports, issue audit observations and follow-through to ensure satisfactory resolution and closure of each internal audit.
  • Coordinate front room/ back room activities for health authority audits and independent audits; manage audit responses and observation resolution.
  • Drive site compliance to regulatory, enterprise, and global requirements through building positive relationships across functions, to meet unified business objectives.
  • As required, run reports and conduct data analysis to support monitoring of key performance indicators; support the preparation of compliance data for the monthly CRB & quarterly QSMR presentations.
  • Fulfills the Quality System audit module site key user responsibilities - represent the Raritan site in global forums/ team meetings, mentor site users for audit process, and control access to any systems used to support audits/inspections.
  • Provide support to quality systems team, ad hoc, for activities such as annual product review, site risk register, or internal quality agreements.
  • Develops and delivers training for specific quality system topics, in both classroom setting and individual interactions
  • Support the creation, assessment and closure as needed of corrective actions, change controls, or audit actions related to the site
  • Ensures and maintains a state of inspection readiness.
  • Perform compliance walkthroughs as part of audit/inspection readiness activities to ensure that the site is an inspection ready state.
  • Perform tasks in a manner consistent with the safety policies, quality systems and cGMP requirements.

Legend Biotech develops and commercializes cell therapies aimed at treating serious diseases, particularly cancers like hematological malignancies and solid tumors. Their approach is technology agnostic, allowing them to explore various methods to find effective treatments. The company operates within the personalized medicine sector, focusing on discovering, developing, and bringing new therapies to market. They generate revenue through licensing and selling their therapies, including CAR-T therapies, which involve modifying a patient's own cells to combat cancer. Legend Biotech emphasizes transparency with investors, regularly updating them on financial results and business developments, setting them apart in the biotechnology field.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Franklin Township, New Jersey

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • $150M investment in Belgium facility shows commitment to expanding production capabilities.
  • Alan Bash's appointment strengthens leadership in CAR-T therapy market.
  • New R&D facility in Philadelphia focuses on next-generation cell therapies.

What critics are saying

  • Increased competition from Amgen's Imdelltra could impact market share.
  • Collaboration with Multiply Labs may face challenges in scaling up production.
  • Expansion of R&D facilities requires significant investment, potentially straining resources.

What makes Legend Biotech unique

  • Legend Biotech focuses on novel cell therapies for oncology, including CAR-T and NK cells.
  • The company is technology agnostic, exploring multiple platforms for effective treatments.
  • Legend Biotech's business model includes discovery, development, and commercialization of therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Sick Leave

Paid Holidays

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Fierce Pharma
Mar 12th, 2025
J&J, Legend to invest $150M in Belgium cell therapy facility as new Carvykti rival looms

J&J, Legend to invest $150M in Belgium cell therapy facility as new Carvykti rival looms.

The Yellow Brick Road
Mar 3rd, 2025
YB new stock pitches (Mon, Mar 3)

Legend Biotech Corporation (LEGN) is developing a promising CAR-T cancer drug in partnership with Johnson & Johnson.

ROI-NJ
Nov 5th, 2024
Legend Biotech Names Alan Bash As Leader Of Its Cer-T Product

Legend Biotech Corporation on Tuesday said it appointed Alan Bash as president of its CAR-T product CARVYKTI®. In this newly created role, Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing the Somerset-based firm’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” Ying Huang, chief executive officer of Legend Biotech said. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Previously, Bash served as chief executive officer for two oncology-focused biotech companies, most recently at ZielBio, and before that, as president and CEO at Checkmate Pharmaceuticals. He also had a 23-year career with Bristol Myers Squibb, where he held various leadership positions across all major therapeutic areas—including oncology—driving the U.S. launch of Opdivo® and the expansion of additional cancer treatments such as Yervoy® and Erbitux ®.Bash contributed to several blockbuster products in collaboration with other companies, including Abilify® with Otsuka and Eliquis® with Pfizer.“As the fastest launched CAR-T product on the market, CARVYKTI has already produced impressive momentum,” Bash said

GlobeNewswire
Nov 4th, 2024
Legend Biotech Appoints Alan Bash As President Of Carvykti(R)

SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the Company’s President of CARVYKTI®. In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Mr

BioBuzz
Oct 30th, 2024
Legend Biotech Chooses Philadelphia for New R&D Center

With a global workforce of 1,500 employees, including 350 in R&D, Legend is expanding its manufacturing capabilities with new facilities in New Jersey and beyond.